Trevi Therapeutics

Q2 FY2026 EarningsQ2 FY26 results were largely in-line with consensus on EPS ($ -0.11 vs. $ -0.11 expected), though the net loss of $17.8M was slightly wider than the $16.9M mean estimate due to accelerating clinical trial activity. The company significantly strengthened its balance sheet via a $162.3M offering in April, extending its cash runway into 2030. Key pipeline progress includes the initiation of the Phase 3 OCEAN-1 trial and Phase 2b LAKE trial, with the Phase 3 OCEAN-2 trial expected to start in Q3 FY26.